Immunotherapy for COVID-19 patients and as a preventive treatment for at-risk individuals

The available data seem to indicate that protective antibody responses are generated during COVID-19 infection. This project examines the antibodies generated in response to infection by SARS-CoV-2 and the production of specific antibodies to provide therapy for COVID-19 patients and as a preventive treatment for at-risk individuals.

The antibodies generated could be administered to infected patients to help reduce the spread of the virus inside the respiratory tract and block the infection of the lower respiratory tract. In addition, these antibodies may also help prevent the infection of high-risk individuals (those potentially exposed to the virus, such as hospital professionals or people at high risk).

Principal investigator: Dr. Giuliana Magri. Researcher in the IMIM's Inflammatory and Cardiovascular Processes Programme
Funding: Partial Generalitat de Catalunya, pending full funding.
Make a donation